Skip to main content
University of California San Francisco
About UCSF
Search UCSF
UCSF Medical Center
Radiology
Search
About
People
Opportunity and Outreach
Wellbeing and Professional Climate
Make a Gift
Contact Us
Patient Care
For Health Professionals
For Patients
Services Offered
Clinical Divisions
Patient Safety
Education
Diagnostic Radiology Residency
Integrated IR Residency
Independent IR Residency
NucMed Residency & Fellowship
Fellowships
T32 Program
Medical Student Education
Master of Science in Biomedical Imaging (MSBI)
Continuing Medical Education
The Margulis Society for Alumni
Distinguished Lecture Series
Research
Research Directory
Imaging Research Symposium
Research Conference
UCSF Radiology at RSNA
Core Services
Academic Affairs
Academic Recruitment
Academic Advancement
Development & Courses
Faculty Mentoring
Faculty Thrive Guide
Celebrating Faculty & Alumni
Department Committees
FAQs
Locations
News
Events
Honors and Awards
Department Publications
Breadcrumb
Home
/
About
/
People
/
Thomas Hope, MD
/
Publications
Thomas Hope, MD's Publications
4D-MRI at 0.55T for internal target volume delineation in liver radiation therapy planning.
A global effort to benchmark predictive models and reveal mechanistic diversity in long-term stroke outcomes.
Added Value of Whole-Body Diffusion-Weighted Imaging in Patients Undergoing Prostate-Specific Membrane Antigen Positron Emission Tomography.
Appropriate use of tissue sampling and somatostatin receptor PET imaging in the diagnosis of pancreatic neuroendocrine tumors: results of an International Delphi Consensus.
Association of Prior PARP Inhibitor Exposure with Clinical Outcomes after 177Lu-PSMA-617 in Men with Castration-resistant Prostate Cancer and Mutations in DNA Homologous Recombination Repair Genes.
Can 177Lu-DOTATATE Kidney Absorbed Doses be Predicted from Pretherapy SSTR PET? Findings from Multicenter Data.
Darolutamide plus androgen-deprivation therapy in high-risk biochemical recurrence of prostate cancer (ARASTEP).
Early changes of PSMA PET expression after initiation of androgen receptor signaling inhibitors in CRPC: an international multicenter retrospective study.
Flip Angle Optimization for Hepatobiliary Phase MRI at 0.55 T in Patients With Metastatic Neuroendocrine Tumors: A Prospective Study.
Funding Reductions Threaten the Future of Medical Innovation.
Low- and High-Volume Disease in Metastatic Hormone-Sensitive Prostate Cancer: From CHAARTED to PSMA PET-An International Multicenter Retrospective Study.
Pre- or post-chemotherapy: effect on PSMA uptake.
Prostate-specific membrane antigen positron emission tomography/computed tomography imaging as a precision diagnostic at prostate cancer recurrence after radical prostatectomy: Modeling long-term survival.
Safety, Dosimetry, and Feasibility of [68Ga]Ga-PSMA-R2 as an Imaging Agent in Patients with Biochemical Recurrence or Metastatic Prostate Cancer.
SNMMI Procedure Standard/EANM Practice Guideline for Fibroblast Activation Protein (FAP) PET.
SPARC: The Standardised Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography Analysis and Reporting Consensus: A Delphi Analysis.
Summary: SNMMI/ACNM Procedure Standard for Posttreatment Imaging of 177Lu-Based Radiopharmaceuticals.
Systemic Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer: ASCO Guideline Update.
The Role of PSMA PET Parameters as Biomarkers for Response to PSMA-Targeted Radiopharmaceutical Therapy.
Updated Prostate Cancer Risk Groups by Prostate-specific Membrane Antigen Positron Emission Tomography Prostate Cancer Molecular Imaging Standardized Evaluation (PPP2): Results from an International Multicentre Registry Study.
Utility of metastasis-directed radiotherapy with and without hormonal therapy in management of oligometastatic prostate cancer.
68Ga-FAP-2286 PET of Solid Tumors: Biodistribution, Dosimetry, and Comparison with 18F-FDG.
Assessing Response to PSMA Radiopharmaceutical Therapies with Single SPECT Imaging at 24 Hours After Injection.
Assessment of lesion insertion tool in pelvis PET/MR data with applications to attenuation correction method development.
Assessment of response to PRRT including anatomical and molecular imaging as well as novel biomarkers.
Beyond Prostate Imaging Reporting and Data System: Combining Magnetic Resonance Imaging Prostate Imaging Reporting and Data System and Prostate-Specific Membrane Antigen-Positron Emission Tomography/Computed Tomography PRIMARY Score in a Composite (P) Sco
Comparison of 18F-DCFPyL and 68Ga-PSMA-11 for 177Lu-PSMA-617 therapy patient selection.
Corrigendum to "Impact of Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography on Prostate Cancer Salvage Radiotherapy Management: Results from a Prospective Multicenter Randomized Phase 3 Trial (PSMA-SRT NCT03582774)" [Eur
Critical updates in neuroendocrine tumors: Version 9 American Joint Committee on Cancer staging system for gastroenteropancreatic neuroendocrine tumors.
Diagnostic and Therapeutic Application of Fibroblast Activation Protein Inhibitors in Oncologic and Nononcologic Diseases.
Efficacy and Toxicity of [177Lu]Lu-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer: Results from the U.S. Expanded-Access Program and Comparisons with Phase 3 VISION Data.
Genomic Correlates of Prostate-Specific Membrane Antigen Expression and Response to 177Lu-PSMA-617: A Retrospective Multicenter Cohort Study.
Impact of Posttreatment SPECT/CT on Patient Management During 177Lu-PSMA-617 Radiopharmaceutical Therapy.
Impact of Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography on Prostate Cancer Salvage Radiotherapy Management: Results from a Prospective Multicenter Randomized Phase 3 Trial (PSMA-SRT NCT03582774).
Implementing evidence-based strategies for men with biochemically recurrent and advanced prostate cancer: Consensus recommendations from the US Prostate Cancer Conference 2024.
Initial Experience with 68Ga-FAP-2286 PET Imaging in Patients with Urothelial Cancer.
Management of Patients with Advanced Prostate Cancer. Report from the 2024 Advanced Prostate Cancer Consensus Conference (APCCC).
Mixed Supervision of Histopathology Improves Prostate Cancer Classification From MRI.
MRI Predicts Residual Disease and Outcomes in Watch-and-Wait Patients with Rectal Cancer.
Novel Radiopharmaceuticals and Future of Theranostics in Genitourinary Cancers.
Pathologic outcome of incidentally detected tracer-avid lesions in 68Ga-PSMA-11 PET/CT for prostate cancer.
Pharmacokinetic Comparison of Selective Prostatic Arterial and Intravenous PSMA PET/CT Radioligand Infusions in Primary Prostatic Adenocarcinoma.
Prostate-specific Membrane Antigen Positron Emission Tomography-detected Disease Extent and Overall Survival of Patients with High-risk Nonmetastatic Castration-resistant Prostate Cancer: An International Multicenter Retrospective Study.
PSMA PET AUC Updates: Inclusion of rh-PSMA-7.3.
PSMA-Targeted Radiopharmaceuticals for Prostate Cancer Diagnosis and Therapy.
Real-World Experience with 177Lu-PSMA-617 Radioligand Therapy After Food and Drug Administration Approval.
Reproducibility and Accuracy of the PRIMARY Score on PSMA PET and of PI-RADS on Multiparametric MRI for Prostate Cancer Diagnosis Within a Real-World Database.
Rethinking Dosimetry: The Perils of Extrapolated External-Beam Radiotherapy Constraints to Radionuclide Therapy.
Technical note: Errors introduced when using Dose Voxel Kernels for estimating absorbed dose from radiopharmaceutical therapies involving alpha emitters.
The Impact of Posttreatment Imaging in Peptide Receptor Radionuclide Therapy.
68Ga-FAPI PET/CT Interobserver Agreement on Tumor Assessment: An International Multicenter Prospective Study.
Baseline tumor growth rate highlights the heterogeneity of well differentiated gastroenteropancreatic neuroendocrine tumors and predicts for increases in Ki67 index over time.
Consensus report of the 2021 National Cancer Institute neuroendocrine tumor clinical trials planning meeting.
Correction to: PET/MRI in colorectal and anal cancers: an update.
Do Bone Scans Overstage Disease Compared with PSMA PET at Initial Staging? An International Multicenter Retrospective Study with Masked Independent Readers.
Editorial Comment.
Imaging of Anal Squamous Cell Carcinoma: Survey Results and Expert Opinion from the Rectal and Anal Cancer Disease-Focused Panel of the Society of Abdominal Radiology.
International EANM-SNMMI-ISMRM consensus recommendation for PET/MRI in oncology.
Joint EANM/SNMMI procedure guideline for the use of 177Lu-labeled PSMA-targeted radioligand-therapy (177Lu-PSMA-RLT).
Pancreatic neuroendocrine tumors: tailoring imaging to specific clinical scenarios.
Pembrolizumab alone and pembrolizumab plus chemotherapy in previously treated, extrapulmonary poorly differentiated neuroendocrine carcinomas.
PET/MRI in colorectal and anal cancers: an update.
Presurgical 68Ga-PSMA-11 Positron Emission Tomography for Biochemical Recurrence Risk Assessment: A Follow-up Analysis of a Multicenter Prospective Phase 3 Imaging Trial.
Prostate-specific Membrane Antigen Reporting and Data System Version 2.0.
PSMA PET Tumor-to-Salivary Gland Ratio to Predict Response to [177Lu]PSMA Radioligand Therapy: An International Multicenter Retrospective Study.
PSMA PET/CT: joint EANM procedure guideline/SNMMI procedure standard for prostate cancer imaging 2.0.
Rectal cancer lexicon 2023 revised and updated consensus statement from the Society of Abdominal Radiology Colorectal and Anal Cancer Disease-Focused Panel.
Second Version of the Prostate Cancer Molecular Imaging Standardized Evaluation Framework Including Response Evaluation for Clinical Trials (PROMISE V2).
Single-dose 177Lu-PSMA-617 followed by maintenance pembrolizumab in patients with metastatic castration-resistant prostate cancer: an open-label, dose-expansion, phase 1 trial.
SNMMI Consensus Statement on Patient Selection and Appropriate Use of 177Lu-PSMA-617 Radionuclide Therapy.
SNMMI Procedure Standard/EANM Practice Guideline for SSTR PET: Imaging Neuroendocrine Tumors.
Systemic Therapy Update on 177Lutetium-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer: ASCO Guideline Rapid Recommendation Q and A.
ACR-ACNM-ASTRO-SNMMI Practice Parameter for Lutetium-177 (Lu-177) DOTATATE Therapy.
ACR-ACNM-ASTRO-SNMMI Practice Parameter for Lutetium-177 (Lu-177) DOTATATE Therapy.
Best Approaches and Updates for Prostate Cancer Biochemical Recurrence.
Choice Is Good at Times: The Emergence of [64Cu]Cu-DOTATATE-Based Somatostatin Receptor Imaging in the Era of [68Ga]Ga-DOTATATE.
Considerations on Integrating Prostate-Specific Membrane Antigen Positron Emission Tomography Imaging Into Clinical Prostate Cancer Trials by National Clinical Trials Network Cooperative Groups.
Dosimetry in radionuclide therapy: the clinical role of measuring radiation dose.
Imaging joint infections using D-methyl-11C-methionine PET/MRI: initial experience in humans.
Impact of Implicit Abdominal Aortic Aneurysm Screening in the Veterans Affairs Health Care System Over 10 Years.
Impact of radiopharmaceutical therapy (177Lu, 225Ac) microdistribution in a cancer-associated fibroblasts model.
Leadership in Patient Advocacy: A Conversation Between Josh Mailman and Thomas Hope.
Management of Patients with Recurrent and Metachronous Oligometastatic Prostate Cancer in the Era of PSMA PET.
Neuroendocrine Tumors and Peptide Receptor Radionuclide Therapy: When Is the Right Time?
PSMA PET in Prostate Cancer-A Biomarker or a Surrogate End Point?-Reply.
Reply: Single-Time-Point Tumor Dosimetry Assuming Normal Distribution of Tumor Kinetics.
Serial stereotactic body radiation therapy for oligometastatic prostate cancer detected by novel PET-based radiotracers.
Synthetic PET via Domain Translation of 3-D MRI.
The PRIMARY Score: Using Intraprostatic 68Ga-PSMA PET/CT Patterns to Optimize Prostate Cancer Diagnosis.
Updates to Appropriate Use Criteria for PSMA PET.
Using PSMA imaging for prognostication in localized and advanced prostate cancer.
A bicentric retrospective analysis of clinical utility of 18F-fluciclovine PET in biochemically recurrent prostate cancer following primary radiation therapy: is it helpful in patients with a PSA rise less than the Phoenix criteria?
A Comprehensive Assessment of 68Ga-PSMA-11 PET in Biochemically Recurrent Prostate Cancer: Results from a Prospective Multicenter Study on 2,005 Patients.
A cost-utility analysis of 18F-fluorocholine-positron emission tomography imaging for localizing primary hyperparathyroidism in the United States.
A Path to Qualification of PET/MRI Scanners for Multicenter Brain Imaging Studies: Evaluation of MRI-Based Attenuation Correction Methods Using a Patient Phantom.
Accuracy of 18F-Fluorocholine PET for the Detection of Parathyroid Adenomas: Prospective Single-Center Study.
Appropriate Use Criteria for Prostate-Specific Membrane Antigen PET Imaging.
Assessment and Comparison of 18F-Fluorocholine PET and 99mTc-Sestamibi Scans in Identifying Parathyroid Adenomas: A Metaanalysis.
Attenuation Coefficient Estimation for PET/MRI With Bayesian Deep Learning Pseudo-CT and Maximum-Likelihood Estimation of Activity and Attenuation.
Diagnostic Accuracy of 68Ga-PSMA-11 PET for Pelvic Nodal Metastasis Detection Prior to Radical Prostatectomy and Pelvic Lymph Node Dissection: A Multicenter Prospective Phase 3 Imaging Trial.
Discovery and characterization of circulating tumor cell clusters in neuroendocrine tumor patients using nanosubstrate-embedded microchips.
Dosimetry in Clinical Radiopharmaceutical Therapy of Cancer: Practicality Versus Perfection in Current Practice.
E-PSMA: the EANM standardized reporting guidelines v1.0 for PSMA-PET.
Effect of microdistribution of alpha and beta-emitters in targeted radionuclide therapies on delivered absorbed dose in a GATE model of bone marrow.
Evaluation of attenuation correction in PET/MRI with synthetic lesion insertion.
Harmonization of PET image reconstruction parameters in simultaneous PET/MRI.
High-Specific-Activity-131I-MIBG versus 177Lu-DOTATATE Targeted Radionuclide Therapy for Metastatic Pheochromocytoma and Paraganglioma.
More Answers and More Questions About Radiotherapy for Metastatic Prostate Cancer.
Oliver Sartor Talks with Thomas A. Hope, Jeremie Calais, and Wolfgang P. Fendler About FDA Approval of PSMA.
Perspectives on Radiopharmaceutical Agents from the FDA: A Conversation between Lou Marzella, Johannes Czernin, and Thomas Hope.
Pitfalls on PET/MRI.
Preoperative risk stratification of lymph node metastasis for non-functional pancreatic neuroendocrine neoplasm: An international dual-institutional study.
Prostate-specific membrane antigen (PSMA)-based imaging in localized and advanced prostate cancer: a narrative review.
Prostate-specific Membrane Antigen and Fluciclovine Transporter Genes are Associated with Variable Clinical Features and Molecular Subtypes of Primary Prostate Cancer.
Prostate-specific Membrane Antigen PET in Prostate Cancer.
PSMA PET Validates Higher Rates of Metastatic Disease for European Association of Urology Biochemical Recurrence Risk Groups: An International Multicenter Study.
PSMA-targeted radiopharmaceutical therapy in patients with metastatic castration-resistant prostate cancer.
Reply: Disparities in PET Imaging of Prostate Cancer at a Tertiary Academic Medical Center.
RESIST-PC: U.S. Academic Foray into PSMA Theranostic Trials.
Response to "Preoperative localization in primary hyperparathyroidism: Views from the developing world".
Somatostatin Receptor Imaging and Theranostics: Current Practice and Future Prospects.
Superior sensitivity of 18F-fluorocholine: PET localization in primary hyperparathyroidism.
The North American Neuroendocrine Tumor Society Consensus Guidelines for Surveillance and Management of Metastatic and/or Unresectable Pheochromocytoma and Paraganglioma.
The Role of PSMA PET/CT and PET/MRI in the Initial Staging of Prostate Cancer.
Tumor Response to Radiopharmaceutical Therapies: The Knowns and the Unknowns.
Use of advanced PET-volume metrics predicts risk of local recurrence and overall survival in anal cancer.
68Ga-PSMA-11 PET/MRI: determining ideal acquisition times to reduce noise and increase image quality.
A Conversation Between Joseph Osborne and Thomas Hope.
A Conversation with John Sunderland, Johannes Czernin, and Thomas Hope.
A novel stratification of mesenteric mass involvement as a predictor of challenging mesenteric lymph node dissection by minimally invasive approach for ileal neuroendocrine tumors.
A Subcutaneous Implant of Tenofovir Alafenamide Fumarate Causes Local Inflammation and Tissue Necrosis in Rabbits and Macaques.
Appropriate Use Criteria for Imaging Evaluation of Biochemical Recurrence of Prostate Cancer After Definitive Primary Treatment.
Bone material analogues for PET/MRI phantoms.
Bringing proportional recovery into proportion: Bayesian modelling of post-stroke motor impairment.
Commonwealth Neuroendocrine Tumour Research Collaboration and the North American Neuroendocrine Tumor Society Guidelines for the Diagnosis and Management of Patients With Lung Neuroendocrine Tumors: An International Collaborative Endorsement and Update of
Disparities in PET Imaging for Prostate Cancer at a Tertiary Academic Medical Center.
Evaluating determinants of receipt of molecular imaging in biochemical recurrent prostate cancer.
Factors Predicting Metastatic Disease in 68Ga-PSMA-11 PET-Positive Osseous Lesions in Prostate Cancer.
False positive PSMA PET for tumor remnants in the irradiated prostate and other interpretation pitfalls in a prospective multi-center trial.
From Compassionate Use to Phase 3 Trial: The Impact of Germany's PSMA-617 Literature.
Gallium-68 prostate-specific membrane antigen ([68Ga]Ga-PSMA-11) PET for imaging of thyroid cancer: a feasibility study.
Impact of 68Ga-PSMA-11 PET on the Management of Recurrent Prostate Cancer in a Prospective Single-Arm Clinical Trial.
Intraarterial Peptide Receptor Radionuclide Therapy Using 90Y-DOTATOC for Hepatic Metastases of Neuroendocrine Tumors.
Introduction to the D-SPECT for Technologists: Workflow Using a Dedicated Digital Cardiac Camera.
MR-based Attenuation Correction for Brain PET Using 3D Cycle-Consistent Adversarial Network.
NANETS/SNMMI Consensus Statement on Patient Selection and Appropriate Use of 177Lu-DOTATATE Peptide Receptor Radionuclide Therapy.
North American Neuroendocrine Tumor Society Guide for Neuroendocrine Tumor Patient Health Care Providers During COVID-19.
NRG Oncology Updated International Consensus Atlas on Pelvic Lymph Node Volumes for Intact and Postoperative Prostate Cancer.
Optimum Imaging Strategies for Advanced Prostate Cancer: ASCO Guideline.
Peptide Receptor Radionuclide Therapy During the COVID-19 Pandemic: Are There Any Concerns?
PET/Magnetic Resonance Imaging Applications in Abdomen and Pelvis.
The North American Neuroendocrine Tumor Society Consensus Guidelines for Surveillance and Medical Management of Pancreatic Neuroendocrine Tumors.
The North American Neuroendocrine Tumor Society Consensus Paper on the Surgical Management of Pancreatic Neuroendocrine Tumors.
Update from PSMA-SRT Trial NCT03582774: A Randomized Phase 3 Imaging Trial of Prostate-specific Membrane Antigen Positron Emission Tomography for Salvage Radiation Therapy for Prostate Cancer Recurrence Powered for Clinical Outcome.
Updates to the Appropriate-Use Criteria for Somatostatin Receptor PET.
111In-Pentetreotide Scintigraphy Versus 68Ga-DOTATATE PET: Impact on Krenning Scores and Effect of Tumor Burden.
18F-fluciclovine PET-CT and 68Ga-PSMA-11 PET-CT in patients with early biochemical recurrence after prostatectomy: a prospective, single-centre, single-arm, comparative imaging trial.
A multi-disciplinary model of survivorship care following definitive chemoradiation for anal cancer.
Assessment of 68Ga-PSMA-11 PET Accuracy in Localizing Recurrent Prostate Cancer: A Prospective Single-Arm Clinical Trial.
AUTHOR REPLY.
Author Reply.
Can the Injected Dose Be Reduced in 68Ga-PSMA-11 PET/CT While Maintaining High Image Quality for Lesion Detection?
Complete Response and Immune-Mediated Adverse Effects With Checkpoint Blockade: Treatment of Mismatch Repair-Deficient Colorectal Neuroendocrine Carcinoma.
Correlation of DOTATOC Uptake and Pathologic Grade in Neuroendocrine Tumors.
EANM procedure guidelines for radionuclide therapy with 177Lu-labelled PSMA-ligands (177Lu-PSMA-RLT).
Ectopic Thyroid-Stimulating Hormone-Secreting Pituitary Adenoma of the Nasopharynx Diagnosed by Gallium 68 DOTATATE Positron Emission Tomography/Computed Tomography.
Genomic Risk Predicts Molecular Imaging-detected Metastatic Nodal Disease in Prostate Cancer.
Hormone receptor expression of colorectal cancer diagnosed during the peri-partum period.
Intertumoral Heterogeneity of 18F-FDG and 68Ga-PSMA Uptake in Prostate Cancer Pulmonary Metastases.
Location of Recurrence by Gallium-68 PSMA-11 PET Scan in Prostate Cancer Patients Eligible for Salvage Radiotherapy.
Mucinous rectal cancer: concepts and imaging challenges.
NANETS/SNMMI Procedure Standard for Somatostatin Receptor-Based Peptide Receptor Radionuclide Therapy with 177Lu-DOTATATE.
Proceedings: Pathways for Successful Translation of New Imaging Agents and Modalities-Phase III Studies.
Prognostic impact of a large mesenteric mass >2 cm in ileal neuroendocrine tumors.
Prostate-Specific Membrane Antigen Ligand Positron Emission Tomography in Men with Nonmetastatic Castration-Resistant Prostate Cancer.
Rectal cancer lexicon: consensus statement from the society of abdominal radiology rectal & anal cancer disease-focused panel.
Residual tumor volume discriminates prognosis after surgery for neuroendocrine liver metastasis.
Single-Center Prospective Evaluation of 68Ga-PSMA-11 PET in Biochemical Recurrence of Prostate Cancer.
Spatial gradients of healthy aging: a study of myelin-sensitive maps.
Summary of the First ISMRM-SNMMI Workshop on PET/MRI: Applications and Limitations.
Synthesis and Initial Biological Evaluation of Boron-Containing Prostate-Specific Membrane Antigen Ligands for Treatment of Prostate Cancer Using Boron Neutron Capture Therapy.
The use of PET/MRI for imaging rectal cancer.
What is the best PET target for early biochemical recurrence of prostate cancer?-Authors' reply.
Clinical Evaluation of 68Ga-PSMA-II and 68Ga-RM2 PET Images Reconstructed With an Improved Scatter Correction Algorithm.
Correction to: LI-RADS technical requirements for CT, MRI, and contrast-enhanced ultrasound.
Developing an efficient phase-matched attenuation correction method for quiescent period PET in abdominal PET/MRI.
Diagnostic Accuracy of 68Ga-PSMA-11 PET/MRI Compared with Multiparametric MRI in the Detection of Prostate Cancer.
Does Extended PET Acquisition in PET/MRI Rectal Cancer Staging Improve Results?
Evaluation of an abbreviated screening MRI protocol for patients at risk for hepatocellular carcinoma.
Ferumoxytol-enhanced MRI in the peripheral vasculature.
Heterogeneous Flare in Prostate-specific Membrane Antigen Positron Emission Tomography Tracer Uptake with Initiation of Androgen Pathway Blockade in Metastatic Prostate Cancer.
Imaging Prostate Cancer With Prostate-Specific Membrane Antigen PET/CT and PET/MRI: Current and Future Applications.
Impact of long-term androgen deprivation therapy on PSMA ligand PET/CT in patients with castration-sensitive prostate cancer.
Impact of Staging 68Ga-PSMA-11 PET Scans on Radiation Treatment Plansin Patients With Prostate Cancer.
Letter to the editor response.
LI-RADS M (LR-M): definite or probable malignancy, not specific for hepatocellular carcinoma.
LI-RADS technical requirements for CT, MRI, and contrast-enhanced ultrasound.
Metaanalysis of 68Ga-PSMA-11 PET Accuracy for the Detection of Prostate Cancer Validated by Histopathology.
PET/MR Imaging of the Pancreas.
PET/MRI for Gastrointestinal Imaging: Current Clinical Status and Future Prospects.
Phase I Study of CTT1057, an 18F-Labeled Imaging Agent with Phosphoramidate Core Targeting Prostate-Specific Membrane Antigen in Prostate Cancer.
Prostate cancer PET tracers: essentials for the urologist.
Scatter Artifact with Ga-68-PSMA-11 PET: Severity Reduced With Furosemide Diuresis and Improved Scatter Correction.
Solitary Mucinous Prostate Adenocarcinoma Lung Metastasis Detected by 68Ga-PSMA-11 PET/CT.
Tumor cell heterogeneity and resistance; report from the 2018 Coffey-Holden Prostate Cancer Academy Meeting.
Variable refocusing flip angle single-shot fast spin echo imaging of liver lesions: increased speed and lesion contrast.
WITHDRAWN: PSMA-PET: a maturing tool.
Zero TE-based pseudo-CT image conversion in the head and its application in PET/MR attenuation correction and MR-guided radiation therapy planning.
18F Fluorocholine PET/MR Imaging in Patients with Primary Hyperparathyroidism and Inconclusive Conventional Imaging: A Prospective Pilot Study.
68Ga-PSMA PET/CT: Joint EANM and SNMMI procedure guideline for prostate cancer imaging: version 1.0.
68Ga-PSMA-11 PET/CT Interobserver Agreement for Prostate Cancer Assessments: An International Multicenter Prospective Study.
Appropriate Use Criteria for Somatostatin Receptor PET Imaging in Neuroendocrine Tumors.
Change in Liver Imaging Reporting and Data System Characterization of Focal Liver Lesions Using Gadoxetate Disodium Magnetic Resonance Imaging Compared With Contrast-Enhanced Computed Tomography.
Diagnostic performance of computed tomography for parathyroid adenoma localization; a systematic review and meta-analysis.
Evaluation of Sinus/Edge-Corrected Zero-Echo-Time-Based Attenuation Correction in Brain PET/MRI.
Hybrid ZTE/Dixon MR-based attenuation correction for quantitative uptake estimation of pelvic lesions in PET/MRI.
Impact of 68Ga-PSMA-11 PET on Management in Patients with Biochemically Recurrent Prostate Cancer.
Incidental Detection of Head and Neck Squamous Cell Carcinoma on 68Ga-PSMA-11 PET/CT.
Motion robust high resolution 3D free-breathing pulmonary MRI using dynamic 3D image self-navigator.
Multiple arterial phase MRI of arterial hypervascular hepatic lesions: improved arterial phase capture and lesion enhancement.
Optimal MRI sequences for 68Ga-PSMA-11 PET/MRI in evaluation of biochemically recurrent prostate cancer.
PET/MR Imaging in Gynecologic Oncology.
PET/MRI: Where might it replace PET/CT?
Prostate Cancer Molecular Imaging Standardized Evaluation (PROMISE): Proposed miTNM Classification for the Interpretation of PSMA-Ligand PET/CT.
Quantitative Evaluation of Atlas-based Attenuation Correction for Brain PET in an Integrated Time-of-Flight PET/MR Imaging System.
Technical Note: Fast respiratory motion estimation using sorted singles without unlist processing: A feasibility study.
The Role of PET/MR Imaging in Precision Medicine.
Zero-Echo-Time and Dixon Deep Pseudo-CT (ZeDD CT): Direct Generation of Pseudo-CT Images for Pelvic PET/MRI Attenuation Correction Using Deep Convolutional Neural Networks with Multiparametric MRI.
68Ga-PSMA-11 PET Imaging of Response to Androgen Receptor Inhibition: First Human Experience.
Comparison of diffusion-weighted imaging and T2-weighted single shot fast spin-echo: Implications for LI-RADS characterization of hepatocellular carcinoma.
Comparison of hepatocellular carcinoma conspicuity on hepatobiliary phase images with gadoxetate disodium vs. delayed phase images with extracellular cellular contrast agent.
Imaging prediction of residual hepatocellular carcinoma after locoregional therapy in patients undergoing liver transplantation or partial hepatectomy.
Performance of magnetic resonance imaging in the evaluation of first-time and reoperative primary hyperparathyroidism.
Radiation dosimetry of (68)Ga-PSMA-11 (HBED-CC) and preliminary evaluation of optimal imaging timing.
Rate of observation and inter-observer agreement for LI-RADS major features at CT and MRI in 184 pathology proven hepatocellular carcinomas.
Safety and technique of ferumoxytol administration for MRI.
SNMMI Comment on the 2016 Society of Surgical Oncology "Choosing Wisely" Recommendation on the Use of PET/CT in Colorectal Cancer.
Targeted PET imaging for prostate-specific membrane antigen in prostate cancer.
Transient washout of hepatic hemangiomas: Potential pitfall mimicking malignancy.
Combined parenchymal and vascular imaging: High spatiotemporal resolution arterial evaluation of hepatocellular carcinoma.
Correcting for respiratory motion in liver PET/MRI: preliminary evaluation of the utility of bellows and navigated hepatobiliary phase imaging.
Detection of Small Pulmonary Nodules with Ultrashort Echo Time Sequences in Oncology Patients by Using a PET/MR System.
Engineering and characterization of simplified vaginal and seminal fluid simulants.
Greater asymmetric wall shear stress in Sievers' type 1/LR compared with 0/LAT bicuspid aortic valves after valve-sparing aortic root replacement.
Hepatobiliary agents and their role in LI-RADS.
Simultaneous (68)Ga-DOTA-TOC PET/MRI with gadoxetate disodium in patients with neuroendocrine tumor.
Somatostatin imaging of neuroendocrine-differentiated prostate cancer.
Transient respiratory motion artifact during arterial phase MRI with gadoxetate disodium: risk factor analyses.
Vascular Imaging With Ferumoxytol as a Contrast Agent.
MR imaging of diffuse liver disease: from technique to diagnosis.
Neuroendocrine tumors: beyond the abdomen.
Evaluation of Marfan patients status post valve-sparing aortic root replacement with 4D flow.
Functional and molecular imaging techniques in aortic aneurysm disease.
Improvement of gadoxetate arterial phase capture with a high spatio-temporal resolution multiphase three-dimensional SPGR-Dixon sequence.
Evaluation of imatinib mesylate as a possible treatment for nephrogenic systemic fibrosis in a rat model.
Gadolinium accumulation and fibrosis in the liver after administration of gadoxetate disodium in a rat model of active hepatic fibrosis.
Intravenous vasopressin for the prevention of nontarget gastrointestinal embolization during liver-directed cancer treatment: experimental study in a porcine model.
4D flow CMR in assessment of valve-related ascending aortic disease.
Impaired social recognition memory in recombination activating gene 1-deficient mice.
Improved risk assessment for abdominal aortic aneurysm rupture: off-the-wall imaging.
Bicuspid aortic valve: four-dimensional MR evaluation of ascending aortic systolic flow patterns.
Clinical evaluation of aortic coarctation with 4D flow MR imaging.
Four-dimensional flow magnetic resonance imaging with wall shear stress analysis before and after repair of aortopulmonary fistula.
Evaluation of intracranial stenoses and aneurysms with accelerated 4D flow.
Hemodynamics in Normal Cerebral Arteries: Qualitative Comparison of 4D Phase-Contrast Magnetic Resonance and Image-Based Computational Fluid Dynamics.
Initial experience characterizing a type I endoleak from velocity profiles using time-resolved three-dimensional phase-contrast MRI.
Nephrogenic systemic fibrosis in patients with chronic kidney disease who received gadopentetate dimeglumine.
Nephrogenic systemic fibrosis in rats treated with erythropoietin and intravenous iron.
Complete intracranial arterial and venous blood flow evaluation with 4D flow MR imaging.
Images in cardiovascular medicine. Evaluation of bicuspid aortic valve and aortic coarctation with 4D flow magnetic resonance imaging.
Imaging of the thoracic aorta with time-resolved three-dimensional phase-contrast MRI: a review.
Comparison of flow patterns in ascending aortic aneurysms and volunteers using four-dimensional magnetic resonance velocity mapping.
Time-resolved 3D quantitative flow MRI of the major intracranial vessels: initial experience and comparative evaluation at 1.5T and 3.0T in combination with parallel imaging.
